ENYO Pharma
French biotechnology company developing host-targeting therapeutics using its Phy-Science platform to discover and develop first-in-class treatments for viral infections and other diseases.
Notes
ENYO Pharma is a French biotechnology company based in Lyon, developing host-targeting therapeutics for viral infections and other diseases. The company's Phy-Science platform leverages understanding of host-pathogen interactions to identify novel drug targets.
Unlike traditional antivirals that target viral proteins, ENYO's host-targeting approach focuses on human proteins that viruses require for their lifecycle. This strategy may offer advantages in terms of reduced viral resistance and potential broad-spectrum activity against multiple viruses.
The company has programs targeting hepatitis B virus (HBV) and other infectious diseases, and is part of the Sofinnova Partners portfolio.
Team
- Thomas Ardzinski - CEO
- Leadership team available on company website
Additional Research Findings
- Founded in 2014
- Portfolio company of Sofinnova Partners
- Headquarters: Lyon, France
- Phy-Science drug discovery platform
- Host-targeting therapeutic approach
- Focus on viral infections including HBV
- First-in-class mechanisms
- Spun out from academic research
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Sofinnova Partners | Paris, France | biotech-focused | seedseries-a+3 | 23 |